Opium (Opioid) Addiction - Pipeline Review, H2 2015

Published: Oct, 2015 | Pages: 87 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Opium (Opioid) Addiction - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Opium (Opioid) Addiction - Pipeline Review, H2 2015', provides an overview of the Opium (Opioid) Addiction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Opium (Opioid) Addiction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Opium (Opioid) Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Opium (Opioid) Addiction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Opium (Opioid) Addiction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents
 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Opium (Opioid) Addiction Overview 9
Therapeutics Development 10
Pipeline Products for Opium (Opioid) Addiction - Overview 10
Pipeline Products for Opium (Opioid) Addiction - Comparative Analysis 11
Opium (Opioid) Addiction - Therapeutics under Development by Companies 12
Opium (Opioid) Addiction - Therapeutics under Investigation by Universities/Institutes 13
Opium (Opioid) Addiction - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Opium (Opioid) Addiction - Products under Development by Companies 17
Opium (Opioid) Addiction - Products under Investigation by Universities/Institutes 18
Opium (Opioid) Addiction - Companies Involved in Therapeutics Development 19
Alkermes Plc 19
BioDelivery Sciences International, Inc. 20
Camurus AB 21
Celtic Pharmaceutical Holdings L.P. 22
Foresee Pharmaceuticals, LLC 23
Heron Therapeutics, Inc. 24
Indivior Plc 25
INSYS Therapeutics, Inc. 26
Omeros Corporation 27
Pfizer Inc. 28
Relmada Therapeutics, Inc. 29
Titan Pharmaceuticals, Inc. 30
Zynerba Pharmaceuticals, Inc. 31
Opium (Opioid) Addiction - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
(samidorphan + buprenorphine hydrochloride) - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Buprenorphine Hemiadipate Hydrochloride - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
buprenorphine hydrochloride - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
buprenorphine hydrochloride - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
buprenorphine hydrochloride - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
buprenorphine hydrochloride depot - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
buprenorphine hydrochloride ER - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
buprenorphine hydrochloride long acting - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
buprenorphine hydrochloride SR - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
cannabidiol - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Cannabidiol - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
FP-004 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
naltrexone hydrochloride - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
naltrexone hydrochloride - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
OMS-405 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
OMS-527 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
PF-5006739 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
samidorphan - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
TA-CD - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Vaccine for Opium Addiction - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Opium (Opioid) Addiction - Recent Pipeline Updates 69
Opium (Opioid) Addiction - Dormant Projects 77
Opium (Opioid) Addiction - Discontinued Products 78
Opium (Opioid) Addiction - Product Development Milestones 79
Featured News & Press Releases 79
Sep 28, 2015: Braeburn Announces FDA's Acknowledgment of Receipt of Probuphine NDA Resubmission; Agency Action Expected by February 27, 2016 79
Sep 03, 2015: Titan Pharmaceuticals To Present At Rodman & Renshaw 17th Annual Global Investment Conference 80
Aug 31, 2015: Titan Pharmaceuticals Announces Resubmission of the New Drug Application for Probuphine for the Maintenance Treatment of Opioid Addiction 80
Jun 08, 2015: Titan Pharmaceuticals Reports Positive Results From Phase 3 Study of Probuphine for Opioid Addiction 80
Jun 05, 2015: Titan Pharmaceuticals Schedules Conference Call to Review Results From Phase 3 Study of Probuphine for Opioid Addiction 82
Apr 15, 2015: Phase 3 Study Completion on Schedule for Late Q2, 2015 83
Apr 02, 2015: Relmada Therapeutics Set for Busy 2015 in Clinical Trials Developing Drugs for the Lucrative Pain Market 83
Mar 24, 2015: Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study for Novel Oral Formulations of Buprenorphine 84
Feb 24, 2015: Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Novel Oral Formulations of Buprenorphine 85
Jan 06, 2015: Titan Pharmaceuticals to Present at 8th Annual OneMedForum 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 86
Disclaimer 87

List of Tables

Number of Products under Development for Opium (Opioid) Addiction, H2 2015 10
Number of Products under Development for Opium (Opioid) Addiction - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Number of Products under Investigation by Universities/Institutes, H2 2015 13
Comparative Analysis by Late Stage Development, H2 2015 14
Comparative Analysis by Clinical Stage Development, H2 2015 15
Comparative Analysis by Early Stage Development, H2 2015 16
Products under Development by Companies, H2 2015 17
Products under Investigation by Universities/Institutes, H2 2015 18
Opium (Opioid) Addiction - Pipeline by Alkermes Plc, H2 2015 19
Opium (Opioid) Addiction - Pipeline by BioDelivery Sciences International, Inc., H2 2015 20
Opium (Opioid) Addiction - Pipeline by Camurus AB, H2 2015 21
Opium (Opioid) Addiction - Pipeline by Celtic Pharmaceutical Holdings L.P., H2 2015 22
Opium (Opioid) Addiction - Pipeline by Foresee Pharmaceuticals, LLC, H2 2015 23
Opium (Opioid) Addiction - Pipeline by Heron Therapeutics, Inc., H2 2015 24
Opium (Opioid) Addiction - Pipeline by Indivior Plc, H2 2015 25
Opium (Opioid) Addiction - Pipeline by INSYS Therapeutics, Inc., H2 2015 26
Opium (Opioid) Addiction - Pipeline by Omeros Corporation, H2 2015 27
Opium (Opioid) Addiction - Pipeline by Pfizer Inc., H2 2015 28
Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics, Inc., H2 2015 29
Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals, Inc., H2 2015 30
Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2015 31
Assessment by Monotherapy Products, H2 2015 32
Assessment by Combination Products, H2 2015 33
Number of Products by Stage and Target, H2 2015 35
Number of Products by Stage and Mechanism of Action, H2 2015 37
Number of Products by Stage and Route of Administration, H2 2015 39
Number of Products by Stage and Molecule Type, H2 2015 41
Opium (Opioid) Addiction Therapeutics - Recent Pipeline Updates, H2 2015 69
Opium (Opioid) Addiction - Dormant Projects, H2 2015 77
Opium (Opioid) Addiction - Discontinued Products, H2 2015 78